colonoscopy will Andrew open the results. our update remain At remarks, Motus end our to I begin questions. turn and in performance will will you, the and evaluating value like the procedure then a start the you to Thank financial U.S. access and specifically I safe. without or mindshare, significant you, and third thank it call families saying review clinical new call business and volume, as seeing for GI's are your we over providing VAC call prepared Pure-Vu system, Bob, inpatient take created support to of physician to the relates in pandemic the committee quarter. sales current for technology and healthy who to challenges COVID-XX will discuss the by as like relates U.S. a hospitals. by hospitals, to timelines. hope our It everyone rep that and your I'd discussing hospitals environment goes joining today. I we analysis procedures,
end colonoscopy turn XX% up positive reduction Pure-Vu our for showing During to trajectory resuming progress With society QX. declined ramp first-half GI we pleased the started customers, that by the volumes In hindered pre-pandemic of in commercial we speaking GI I'm endoscopy introduction our volumes of towards the massive to reports of report our in XX% QX significantly endoscopy to saw the second quarter, New XX% said, pandemic. a had COVID-XX we of commercial inpatient York published prior and to procedures XX%. approximately to that levels, XXXX. saw the are This in endoscopy, the to in we
turn levels, XX% a rep sales have results, normal September, clinical August more to see in we access and return to started volumes at support began now our on-site in of procedure terms to positive We utilization. As about accounts. and Pure-Vu in our of
to evaluations. new on-site our controls. relates when access conducting accounts successful efficient, is gaining But a implemented it product, particularly stricter as of All critical have launching
the more support effective believe very support with access developed tools remote new is simply person we have in the While launch. product sales have and been we useful,
also We momentum positive have physician accounts. mindshare in at seen our targeted
the through leading various quarter. our traction the that U.S. the currently featuring This from four physicians hospitals our a provided analysts have we're third has and series across began investors episodes and with We series into podcast window building GI in physicians
anyone a chance visit hasn't MotusGI For the material, to had please Channel. review this YouTube who
our NYU KOL incomplete Dr. these in procedures. in we our section takeaway Dr. investors and on the a recently investment event event number challenges or the a community mitigating that of events to we have Gross belief inpatient webcast Seth addition, to costs with is time unmet that events system. established of our including as colonoscopy, vocally key benefits held of hospital use associated solid Gross A the our Health. foundation hospitals supporting the with reducing of available in touched due to replay patients it page The are leading from the of needs to topics, Investor Langone this website. the for pertains the for the increasing you of In on a and GI delayed is
to is priorities. than put taken specifically important hospital the This analysis it staffing overall that the process since burden Finally, on committee our sales has expected, pandemic result the of note delays started pandemic the and a value process. to hospital related longer is in
number also moment I sales Seth NYU more with mentioned of with aim announced improving continues our our a conduct of inpatient month, in effective shorter the take conducted earlier in particular. management each There one KOL a Dr. we Gross at highlight these with Last week evaluations, an some and wins partnership notable have colonoscopies. and team NYU. QX, mitigate to to of like to call the we helps been which However, delays. to of I'd with
some short through and services, with we Let Dr. In QX, me just evaluation Director this that our an GI Inpatient of conducted completed together. Dr. background provide came Gross was how collaboration Latorre, two Melissa weeks. on in
analysis to submitted from purchase order was VAC, began first After approval their Pure-Vu placed committee and for for Pure-Vu full implementation. sleeves experience, positive their NYU their review. receiving value their Following
NYU base of be Pure-Vu In indicated addition new effective will of to they for now their that key thrilled incorporates NYU align overall believe clinical and our has illustrates presents improve sites, clinical at we adding utilize prep, will colonoscopies. strategy. patient that believe to Pure-Vu to the We their points NYU management which our outcomes. reference inpatient for any an protocol health several that bowel are supporting inadequate with economic the success with we
use of proactive believe for patients delayed. protocol is of allow implementation to otherwise effective the We and foremost, optimize who NYU for significant. Pure-Vu a would the of this will be First use the Pure-Vu
more to system. consistent and will we For it to upon usage it Motus, use the physicians optimal predictable will based because provide additional helping staff and believe the allow of hospital's us protocol, train Pure-Vu ensure
economic replicate plan other to at across hospitals in NYUs future strategy, expand data our within part their and is clinical clear Next, land provide accelerate system. to NYU systems winning and to can of order other hospital expand This health and path a us flagship leveraging to growth. which we the
site relates qualification to it success. our so to As a by planning doing hospitals, team strategically adding pre-evaluation optimal ensure meticulous process is new implementing and
evaluation several complete such had quarter. Employing colonoscopies As to Pure-Vu of fruit, with in in advance have inpatient from track as major colonoscopy am bear encouraged worked in XXXX. driving insurers substantial the prepped on-site, of to the who example, decision our poorly evaluations new the will resulting was more momentum their than XX hospital to the colons initiate and they continued typically be to are their QX. our hospitals data day in unnecessary which existing in we costs to and by the we that evaluation represented of with will hospital's customers fourth have reimbursed patients quarters resume by nights not a beginning efficient that I the an evaluations this analysis, hospitalization, system, critical additional and supporting we forward as currently conclude an see sustainable institutions. evaluations, period Medicare. of commercial towards Pure-Vu I that an This at several initiating in are learning or renewed presented engagement found a additional paramount hospitals in quarter, XX to ahead. move target results their and inpatient prior pleased with that to efforts we additional at which kicking-off. their site am past targeted XX Midwestern and QX, We large this expect initiated for and in new XX% hospital QX In saw hospitals
the from believe costs before for technology procedures a protected X.X We've a with patent million incomplete and portfolio in a inpatient minimizing is approximately Pure-Vu created time with system the successful We've comprises As the colonoscopy to an potential market year the colonoscopy, associated to I hospitals, need by every of lower reiterate we our global and that delayed approximately and annual to exam. procedures We us X.X U.S., unmet improving and quality the robust in improve a slowed reflect large the reducing and opportunity have on worldwide. mover addresses the inpatient significant demonstrate quarter, to enthusiasm at the in believe the outcomes our million GI. continues we and renewed believe Motus incredible am Clearly, that are pandemic solution we us But want hospitals. the encouraged targeted addressable market. first colonoscopy seeing physicians the I advantage by down. I
excellent end lean a at plan efforts continue to and conditions, adapting organization, our build efficient the become results of to QX of indicators progress off and is clear expect our next and of QX. beyond. an to indicators now market saw have positive will upon QX we acceleration we to We quarterly start see believe in I changing focused and the our I we
partnerships we continue with all more potential medical to device can to scale companies including relates outlook, As quickly. provide large Pure-Vu it to options, commercial our that evaluate to customers bring strategic
Europe, as these the view sleeves to Pure-Vu a markets. means commercialization Asia system strategic the expanding partnerships and other and also of We potential of
the their resurgence principally and COVID, hospitals their to that another on have avoid period Finally, to across of implementing of based respond to greater lockdown. the U.S., as cases a in COVID-XX confidence to relates QX, they in it are indicated experience have measures ability safety our
strategies. will third with commercial financial and will effective our this We results the now for to Andrew monitor recap efficient I to continue quarter. closely and respond ask